Surgical innovation redefines what is possible for advanced colorectal cancer
Editor's Note Colorectal tumors once considered inoperable are now routinely treated with curative surgery, thanks to advances in multimodality therapy and complex resection techniques, Mayo Clinic September 16 reports. Decades ago, cancers invading the sacrum, pelvic organs, or major blood vessels were often deemed unresectable, leaving patients with only palliative…
Complex aortic surgery shown safe with minimally invasive approach
Editor's Note Minimally invasive surgery can extend beyond valve replacement to complex aortic procedures without sacrificing safety or long-term outcomes. According to an August 21 news update from the University of Miami Miller School of Medicine, a new study of 796 patients found adding ascending aortic or hemiarch replacement to…
Drug that makes tumors glow is transforming cancer surgery
Editor's Note A new drug is giving surgeons a sharper view of cancer in the OR and helping preserve healthy tissue, Fast Company August 28 reports. Cytalux is an FDA-approved fluorescent agent that makes cancer cells glow green under infrared light, allowing surgeons to spot and remove malignant lesions with…
Robotic surgery boosts 3-year relapse-free survival in rectal cancer
Editor's Note Robotic surgery improves 3-year relapse-free survival compared with laparoscopic surgery for rectal cancer, according to findings presented at the 2025 annual meeting of the Society of American Gastrointestinal and Endoscopic Surgeons, published by Gastroenterology & Endoscopy News on August 18. As detailed in the article, researchers conducted a…
Report: Sicker surgical patients fared better post-pandemic
Editor's Note Hospitals achieved a substantial reduction in mortality risk for surgical inpatients between 2019 and 2024, even as patients grew sicker and stayed longer, according to a report released August 5 by the American Hospital Association (AHA) and Vizient. In the first quarter of 2024, hospitalized surgical patients were…
Pembrolizumab sets new standard in advanced head and neck cancer surgery, trial shows
Editor's Note According to results from a randomized trial, titled KEYNOTE-689, adding pembrolizumab (Keytruda) to surgery and standard adjuvant therapy significantly prolongs event-free survival (EFS) in patients with resectable, locally advanced head and neck squamous cell carcinoma (HNSCC), MedPage Today April 28 reports. Experts are calling the findings a major…
Free Daily News
- ACS conference charts bold future for surgical quality with data, teamwork, frontline innovation
- Surgical leaders urged to weigh risks, rewards of innovation with a critical eye
- Health systems report dramatic nurse retention gains through residency, development programs
- Surgical innovation redefines what is possible for advanced colorectal cancer
- CMS proposal to end inpatient only list draws strong industry response
- Fall deaths among older adults have tripled, prescription drugs under scrutiny
- AI could shrink drug discovery from years to months, expert says
- AI vendors bet on guaranteed ROI as competition with Epic intensifies
- AMA 2026 CPT code set expands with AI, remote monitoring, leg revascularization updates
- PACU initiative cuts emergency response times from 9 to 2 minutes